2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2520 Outcomes of patients with extranodal natural killer/T- cell lymphomas (ENKTL) undergoing consolidative hematopoietic cell transplantation (HCT): A CIBMTR analysis

Amrita Desai, MD,MPH, Kwang Wooahn, PhD2, Tiening Chen, MS3, Jinalben Patel, MPH, BDS4, Cameron J. Turtle5, Peter Riedell, MD6, Craig Sauter, MD7, Alex Francisco Herrera, MD8, Mazyar Shadman, MD, MPH9, Kamil Rechache10
1 OHSU Knight Cancer Institute, Portland, Oregon, United States
2 CIBMTR, Milwaukee, Wisconsin, United States
3 CIBMTR, Milwaukee, Wisconsin, United States
4 CIBMTR, Milwaukee, Wisconsin, United States
5 Royal North Shore Hospital, University of Sydney, St Leonards, Sydney, Australia
6 University of Chicago, Chicago, United States
7 Memorial Sloan Kettering Cancer Center, New York, United States
8 City of Hope, Duarte, United States
9 Fred Hutch Cancer Center, Seattle, United States
10 MedStar Georgetown Cancer Institute, Washington, United States

Introduction:

Extranodal Natural Killer/T- cell lymphomas (ENKTL) are rare aggressive lymphomas with poor post relapse survival. Therapeutic advances including the addition of L-asparaginase and immune-check point inhibitors have resulted in improved progression free survival (PFS) and overall survival (OS). However, relapses are common (40-50%) and continue to remain the major cause of mortality in this population. With the lack of randomized prospective trials; the role of autologous and allogeneic HCT as a consolidative approach in first remission or later has been a topic of debate. In this retrospective study we evaluate the role of HCT in the era of novel treatments by analyzing outcomes of a diverse pool of patients with ENKTL.

 

Objectives:

To assess outcomes in patients with ENKTL undergoing autologous and allogeneic HCT including OS, PFS, relapse rate, acute and chronic graft versus host disease (GVHD) and GVHD-free relapse-free survival (GRFS).

 

Methods:

This is a multicenter retrospective study of adults aged ≥18 years with a histologically confirmed diagnosis of ENKTL who underwent either an autologous or allogeneic HCT between 2008-June 2024. OS was analyzed using Kaplan-Meier curves and univariate analysis was done using Cox regression model.

 

Results:

A total of 457 patients underwent HCT; 259 (56.7%) patients received an autologous HCT, and 198 (43.3%) patients received an allogeneic HCT. The median age for the whole cohort was 47.3 years (18.1-78.7) with 65.4% male and 51.6% Caucasian patients. The allogeneic HCT group had more patients receiving 3+ lines of therapy (22.7% vs 9.3%) and a higher number of chemo-resistant cases (8.6% vs 4.6 %) compared to AutoHCT group.

In the autologous stem cell transplant group, 39.8% of patients had an HCT-CI score of 0 and 64.5% of patients had a Karnofsky score of ≥90. BEAM-based conditioning was used in 60.2% of patients and 12.7% receiving TBI-based conditioning. The median time to HCT of 8.8 months (3.1-196.6) and 63.3% of patients underwent HCT within 12 months of diagnosis. At a median follow-up of 60.4 months (3.0-181.3), the 4-year PFS was 46.8% (40.2-53.5) and 4-year OS was 59.8% (53.3-66.1) with a relapse rate of 43.4% (36.9-50.1) and a lower NRM of 9.7 % (6.2-14) at 4 years compared to allogeneic HCT.

In the allogeneic stem cell transplant group, 38.9% of patients had an HCT-CI score of 0 and 61.1% of patients had a Karnofsky score of ≥90. Myeloablative conditioning (MAC) was used in 40.9% of patients and 58.1% received TBI-based conditioning. The median time to transplant 12.1 months (2.6-306.0) and 49.5% of patients were transplanted within one year of diagnosis. Peripheral blood stem cell grafts were used in 91.9% of cases, 43.9% received matched unrelated donors (MUD) and 55.5% got Calcineurin inhibitor based GVHD prophylaxis. At the median follow-up of 45.1 months (2.8-195.2), the 4-year PFS was 40.8% (33.5-48.3) and OS was 43.3% (35.7-51.1), with the 4-year relapse rate of 40.4% (33.4-47.7) and NRM of 18.8% (13.2-25.2). Grade 2 - 4 acute GVHD was 18.9% and grade 3-4 acute GVHD was 6.2%. Chronic GVHD at 1-year was 35.1% (28.2-42.3) and 44.2% (36.6-52) at 3-years with moderate to severe chronic GVHD of 21.5% (15.5-28.2) at 3-years. The GRFS at 1-year was 37.9% (30-46.2) and 29.1% (21.2-37.8) at 4 years. There was no difference in PFS or OS between MAC verses reduced intensity conditioning (RIC) conditioning regimen and when HCT was done after 1-line of treatment verses ≥2 lines of treatment; however, younger age 18-39 years was associated with better OS when compared to 40-65 years [HR 2.44, 95% CI- 1.52-3.93] and age ≥66 years [HR 3.49, 95% CI- 1.60-7.6] respectively.

 

Conclusions:

Our study is the largest reported series on transplant-related outcomes in ENKTL. We show that both Autologous and Allogeneic HCT offer potential for durable control in this highly aggressive disease. However, relapse (~40% at 4-years) continues to remain the biggest challenge. Future studies with post-transplant maintenance strategies and surveillance options are needed to improve outcomes in this cohort.

Amrita Desai, MD,MPH: No relevant conflicts of interest to declare.